摘要
痴呆症的发病率不仅在发达国家而且在人口老龄化上升的发展中国家迅速增长。这一趋势预计将进一步恶化,在未来几十年病例数可能增至三倍。在过去的几十年里,流行病学研究表明血管或生活方式相关因素与阿尔茨海默氏病(AD)和痴呆症的风险增加有关。有关AD的病理生理过程的研究显示AD患者在出现症状前几十年就已开始发生大脑病理性损伤。许多预防研究结果表明身体活动和/或心理训练可以提高AD或轻度认知功能障碍(MCI)者的认知能力和日常生活。然而,早期发现和潜伏期以及基于这些阶段的有效的预防方法等问题仍未解决。因此,我们提出基于潜伏期的预防AD的不同策略:一是涉及身体和心理训练,针对没有发生病理生理变化患者的危险因素。第二种方法非药物和药物相结合的方法,旨在治疗发生淀粉样蛋白沉积改变的MCI患者个人和/或服用淀粉样蛋白级联药物的神经退行性病变患者。一些正在进行的和有前途的试验预计将在未来几年得出试验结果。
关键词: 阿尔茨海默氏病,淀粉样蛋白级联,心理训练,潜伏期的,预防策略,危险因素
Current Alzheimer Research
Title:Editorial (Thematic Issue: Prevention Strategies Targeting Different Preclinical Stages of Alzheimer’s Disease)
Volume: 12 Issue: 6
Author(s): Bin Zhou
Affiliation:
关键词: 阿尔茨海默氏病,淀粉样蛋白级联,心理训练,潜伏期的,预防策略,危险因素
摘要: The incidence of dementia is rapidly increasing not only in developed countries but also in developing countries with rising aging populations. This trend is expected to worsen, with the number of cases possibly tripling in the coming decades. Over the last few decades, epidemiological studies have revealed that vascular-or lifestyle-related factors are associated with an increased risk of Alzheimer’s disease (AD) and dementia. Researches into the pathophysiological processes of AD have revealed that the pathological brain lesions of AD begin decades before the onset of symptoms. Many prevention studies have indicated that physical activity and/or mental training can improve cognition and daily life in subjects with AD or mild cognitive impairment (MCI). However, issues with early detection and preclinical staging and effective preventive approaches that are based on these stages remain unresolved. Therefore, we propose different strategies for AD prevention based on its preclinical stages: one involves physical and mental training that targets the risk factors in subjects without pathophysiological changes, and the second approach combines nonpharmacological and pharmacological methods and aims to treat MCI in individuals with amyloid deposits and/or neurodegeneration with drugs that target the amyloid cascade. The results of several ongoing and promising trials are expected in the next few years.
Export Options
About this article
Cite this article as:
Bin Zhou , Editorial (Thematic Issue: Prevention Strategies Targeting Different Preclinical Stages of Alzheimer’s Disease), Current Alzheimer Research 2015; 12 (6) . https://dx.doi.org/10.2174/1567205012666150530202923
DOI https://dx.doi.org/10.2174/1567205012666150530202923 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evaluation and Management of Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Severe Psychiatric Disorders in Mid-Life and Risk of Dementia in Late- Life (Age 65-84 Years): A Population Based Case-Control Study
Current Alzheimer Research Protective Effects of Isothiocyanates against Alzheimer's Disease
Current Traditional Medicine "Take and Run" and "Take and Hold" Therapeutical Electromagnetic Field Application Modalities in Physiotherapy: Some Clinically Significant Pathways of Action
Current Chemical Biology The Role of TMP21 in Trafficking and Amyloid-β Precursor Protein (APP) Processing in Alzheimer’s Disease
Current Alzheimer Research Current Clinical Applications of Botulinum Toxin
Current Pharmaceutical Design Disorders of Consciousness and Electrophysiological Treatment Strategies: A Review of the Literature and New Perspectives
Current Pharmaceutical Design Biotechnological Approaches for the Treatment of Inflammatory Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Metabolic Syndrome and HIV Infection
Current Pharmaceutical Design Progression of Renal Dysfunction in Patients with Cardiovascular Disease
Current Cardiology Reviews Recent Advances in Ethnopharmacological and Toxicological Properties of Bioactive Compounds from <i>Aloe barbadensis</i> (Miller), <i>Aloe vera</i>
Current Bioactive Compounds Reduced Risk of Incident AD with Elective Statin Use in a Clinical Trial Cohort
Current Alzheimer Research Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders
Current Pharmaceutical Design Screening of Early and Late Onset Alzheimer’s Disease Genetic Risk Factors in a Cohort of Dementia Patients from Liguria, Italy
Current Alzheimer Research Evolving Therapeutic Targets in Ischemic Stroke: A Concise Review
Current Drug Targets Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?
Current Alzheimer Research Gene Therapy: How to Target the Kidney. Promises and Pitfalls
Current Gene Therapy An Apple Plus a Brazil Nut a Day Keeps the Doctors Away: Antioxidant Capacity of Foods and their Health Benefits
Current Pharmaceutical Design Stress, Depression, Resilience and Ageing: A Role for the LPA-LPA1 Pathway
Current Neuropharmacology Neurobiology of Bipolar Disorder: Abnormalities on Cognitive and Cortical Functioning and Biomarker Levels
CNS & Neurological Disorders - Drug Targets